Your browser doesn't support javascript.
loading
Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.
Song, Rui; Qian, Hang; Wang, Yunlian; Li, Qingmei; Li, Dongfeng; Chen, Jishun; Yang, Jingning; Zhong, Jixin; Yang, Handong; Min, Xinwen; Xu, Hao; Yang, Yong; Chen, Jun.
Afiliación
  • Song R; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Qian H; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Wang Y; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Li Q; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Li D; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Chen J; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Yang J; Department of Immunology, School of Basic Medicine, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Zhong J; Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Yang H; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Min X; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Xu H; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Yang Y; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
  • Chen J; Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China.
J Diabetes Res ; 2022: 4554996, 2022.
Article en En | MEDLINE | ID: mdl-35434139
The risk of cardiovascular diseases is closely related to diabetes. Macrovascular disease is the main cause of death and disability in patients with type 2 diabetes. In recent years, the glucagon-like peptide-1 receptor agonist (GLP-1RA), a new type of hypoglycemic drug, has been shown to regulate blood sugar levels, improve myocardial ischemia, regulate lipid metabolism, improve endothelial function, and exert a protective role in the cardiovascular system. This study reviewed the protective effects of GLP-1RA on the cardiovascular system.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Sistema Cardiovascular / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: J Diabetes Res Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Sistema Cardiovascular / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: J Diabetes Res Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido